The European Commission (EC) has approved AstraZeneca’s Qtern (saxagliptin/dapagliflozin) tablets for the treatment of Type 2 diabetes in all 28 European Union member countries plus Iceland, Liechtenstein, and Norway.

Qtern is indicated for adults with Type 2 diabetes aged 18 years and older to improve glycaemic control when metformin and/or sulfonylurea and one of the mono-components of Qtern alone do not provide adequate control, or when a patient is already being treated with the free combination of saxagliptin and dapagliflozin.

AstraZeneca’s diabetes portfolio consists of the three non-insulin, anti-diabetic treatments: SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors. Qtern is a DPP-4i/SGLT-2i combination product.

Source: AstraZeneca